Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels
The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CYP2D6 genotypes and endoxifen levels.
ER+ Breast Cancer
DRUG: Tamoxifen dose adjustment
Effects of genotype and phenotype of CYP2D6 on plasma and serum concentration of tamoxifen and its metabolites, 8 weeks after initial tamoxifen intake|Effects of dose recommendation of tamoxifen based on CYP2D6 genotyping results on endoxifen levels, 8 weeks after dose recommendation|Frequencies of CYP2D6 alleles in female Indonesian population, Baseline, pre-intervention
The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CYP2D6 genotypes and endoxifen levels.